BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. Its proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer.
Discover Small Cap
Join thousands of other Investors following our stock commentary for Free